Discovery of immunopotentiatory drugs: current and future strategies
- 24 November 2002
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 130 (3) , 363-369
- https://doi.org/10.1046/j.1365-2249.2002.02016.x
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848Nature Immunology, 2002
- MAP Kinases in the Immune ResponseAnnual Review of Immunology, 2002
- Successful Treatment of Drug‐Resistant Cutaneous Leishmaniasis in Humans by Use of Imiquimod, an ImmunomodulatorClinical Infectious Diseases, 2001
- In Vitro Immunomodulatory Properties of Tucaresol in HIV InfectionClinical Immunology, 2000
- Review Article Imiquimod applied topically: a novel immune response modifier and new class of drugInternational Journal of Immunopharmacology, 1999
- p-Hydroxyphenylacetaldehyde, the Major Product of l-Tyrosine Oxidation by the Myeloperoxidase-H2O2-Chloride System of Phagocytes, Covalently Modifies ε-Amino Groups of Protein Lysine ResiduesJournal of Biological Chemistry, 1997
- p-Hydroxyphenylacetaldehyde Is the Major Product of L-Tyrosine Oxidation by Activated Human PhagocytesJournal of Biological Chemistry, 1996
- Galactose Oxidation in the Design of Immunogenic VaccinesScience, 1992
- Inosine PranobexDrugs, 1986